Therapy for hepatitis C virus-related cryoglobulinemic vasculitis.
about
Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infectionTreatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug TherapyHepatitis C and kidney disease: A narrative review.Global epidemiology and burden of HCV infection and HCV-related disease.The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review.Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015.Assessment of total hepatitis C virus (HCV) core protein in HCV-related mixed cryoglobulinemiaHepatitis C virus associated glomerulopathies.Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis.Management of patients with hepatitis C infection and renal disease.Thymic stromal lymphopoietin in hepatitis C virus-related cryoglobulinemic vasculitis: gene expression level and protein distribution.Combined Effects of 2 Interleukin 28B Polymorphisms on the Therapeutic Outcome of Hepatitis C Patients With Circulating CryoglobulinsAntiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspectiveDirect-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience.Vasculitis: determinants of disease patterns.HCV Treatments and Their Integration Into Rheumatology.Extrahepatic manifestations of HCV: the role of direct acting antivirals.Why do I treat my patients with mild hepatitis C?Optimum combination therapy regimens for HIV/HCV infection.Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies.Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era.Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.Hepatitis C virus and its cutaneous manifestations: treatment in the direct-acting antiviral era.Vasculitic and autoimmune wounds.[Virus-associated arthritis].From the pathogenesis to the cure of indolent B-cell lymphoproliferative disorders associated with hepatitis C virus infection: which role for direct-acting antivirals?HCV RNA Genomic sequences and HCV-E2 glycoprotein in sural nerve biopsies from HCV-infected patients with peripheral neuropathy.Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis.Vasculitic Diseases and Prothrombotic States Contributing to Delayed Healing In Chronic Wounds.A Rare Case of Hepatitis C-Associated Cryoglobulinemic Duodenal Vasculitis.Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.[Cryoglobulinemic vasculitis].For patients with rheumatic disease and hepatitis C infection: the end of interferon.Case Report of Spontaneous Remission of Biopsy-Proven Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis.Hepatitis C virus infection and its rheumatologic implications.Myopericarditis in a patient with hepatitis C and cryoglobulinemic renal disease.The case for cost-effectively treating cryoglobulinemic vasculitis with interferon-free anti-hepatitis C virus therapy.Transcriptional profiling of PBMCs unravels B cell mediated immunopathogenic imprints of HCV vasculitis.Recovery of hepatitis C specific T-cell responses after rituximab therapy in hepatitis C mixed cryoglobulinemic vasculitis.
P2860
Q24187162-97476580-12D2-4F5D-A6B2-DECF679708B4Q28073100-7C493155-7405-40E6-A7DD-F06E4C328E49Q30238652-E0199ED8-57FB-42DD-8130-EAF757501A8DQ30240220-37442041-45A1-4807-B257-77C794CCD17CQ30251847-CCE69C26-D9ED-46F2-B3D3-088371EB63A0Q30276550-3CC295F2-884D-458B-81F3-4C212E5FBAC8Q31024615-EE930CE2-5D2C-4BC5-86FA-91CD18EE1493Q33766292-8C4E9AF7-3C63-4ECF-8ACD-865600074DD0Q33801278-F983FB3E-A02F-42A2-A79C-E3565C57C794Q34401717-A63AA9D7-35A4-474B-AA50-276A2D75067BQ35127041-3105FE1A-7516-45D7-A77E-64C5F8F8E7DDQ35337340-827E904F-4D1C-464F-BEAD-734B5AC84B8FQ36194392-2D55732C-B097-4FED-A055-A2097FAA7052Q36870118-61DC70BB-35E0-474F-9396-C7F680BB3949Q37742383-CC4201E0-EBBE-4067-9454-905856EBD4ADQ38220637-BB79BAB9-A21C-4CB3-A4A9-D547076BD93FQ38538199-0955A862-C30C-4EC7-95CD-BC2D683958B8Q38684508-C7595C94-02EC-4E15-BF79-BA99D88E8EF8Q38685564-9921F7BB-667E-43BF-A2A9-48790FEF8C79Q38715477-02610FF6-FB96-4F5D-A9DB-1D03E97609ECQ38749694-761F92C7-1BB3-4ACE-8FA8-91FD3843BF04Q38806948-2F8015E5-3B88-46C4-8EF6-77CBFBCE63A3Q38909316-BD0F585D-0E3C-4DF9-8401-17F9E462FFA5Q38933599-71B00868-2915-49B3-B1BE-C626C835925CQ38954003-CCA9FDD2-CEE2-4BAB-B82B-BD627FCF6482Q40054294-E3E22CF2-96D3-44EB-8C68-54060123445FQ40135838-345D89B9-F059-4F0B-8933-28E1300DB8FBQ40185798-F5883FF6-FD36-4EE3-9C46-B66A6B636276Q40362365-DA381BE9-02B4-4771-AF78-8E12751A9B23Q40456740-ADBF8B30-3F69-4480-A821-405EECCE0FCBQ40494317-65AC4F8A-2781-49D6-8665-C5A62C4462B6Q40528517-6A46261F-20BB-4294-B3DF-ED66217BB754Q40733045-32B01575-1556-4F37-93A4-0A35EDB1D73EQ40934454-AF1B95F1-6443-4651-949C-AA19D56D67DEQ41485811-E5284BD7-F9B4-42A8-A96F-37206731AEB3Q41560603-803B847E-F37E-4F60-8257-070E44E15AF0Q42070442-FF9647D1-308D-4BB1-9559-52E4933ACDE9Q43040151-21564F47-06C1-4B52-ACA8-91A35F8E990DQ47171530-2A308999-3789-4A56-A571-3F558033251FQ47298278-0B522723-FE4E-4E43-9541-BF41FE32C46B
P2860
Therapy for hepatitis C virus-related cryoglobulinemic vasculitis.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Therapy for hepatitis C virus-related cryoglobulinemic vasculitis.
@ast
Therapy for hepatitis C virus-related cryoglobulinemic vasculitis.
@en
Therapy for hepatitis C virus-related cryoglobulinemic vasculitis.
@nl
type
label
Therapy for hepatitis C virus-related cryoglobulinemic vasculitis.
@ast
Therapy for hepatitis C virus-related cryoglobulinemic vasculitis.
@en
Therapy for hepatitis C virus-related cryoglobulinemic vasculitis.
@nl
prefLabel
Therapy for hepatitis C virus-related cryoglobulinemic vasculitis.
@ast
Therapy for hepatitis C virus-related cryoglobulinemic vasculitis.
@en
Therapy for hepatitis C virus-related cryoglobulinemic vasculitis.
@nl
P356
P1476
Therapy for hepatitis C virus-related cryoglobulinemic vasculitis.
@en
P2093
Franco Dammacco
P304
P356
10.1056/NEJMRA1208642
P407
P577
2013-09-01T00:00:00Z